Tessa Romero
Stock Analyst at JP Morgan
(4.36)
# 371
Out of 5,091 analysts
72
Total ratings
51.79%
Success rate
21.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $37 → $20 | $27.28 | -26.69% | 7 | Nov 21, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $10.54 | +42.31% | 8 | Nov 20, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $57 → $60 | $44.53 | +34.74% | 3 | Nov 18, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $46 → $47 | $45.25 | +3.87% | 6 | Nov 18, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Underweight | $261 → $263 | $3.50 | +7,414.29% | 1 | Nov 18, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $33 → $31 | $26.76 | +15.84% | 11 | Nov 17, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $22.20 | -23.42% | 7 | Nov 14, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $33 → $34 | $23.56 | +44.31% | 11 | Nov 14, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Underweight | n/a | $2.19 | - | 5 | Sep 16, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $71 → $53 | $64.13 | -17.36% | 5 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $9.45 | +5.82% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $28.97 | +31.17% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $17.18 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $17.82 | +62.74% | 3 | Aug 13, 2024 |
Agios Pharmaceuticals
Nov 21, 2025
Maintains: Neutral
Price Target: $37 → $20
Current: $27.28
Upside: -26.69%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $10.54
Upside: +42.31%
Xenon Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $57 → $60
Current: $44.53
Upside: +34.74%
Scholar Rock Holding
Nov 18, 2025
Maintains: Overweight
Price Target: $46 → $47
Current: $45.25
Upside: +3.87%
Rocket Pharmaceuticals
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $3.50
Upside: +7,414.29%
ACADIA Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $33 → $31
Current: $26.76
Upside: +15.84%
Dyne Therapeutics
Nov 14, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $22.20
Upside: -23.42%
Edgewise Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $23.56
Upside: +44.31%
Neumora Therapeutics
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.19
Upside: -
Cytokinetics
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $64.13
Upside: -17.36%
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $9.45
Upside: +5.82%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $28.97
Upside: +31.17%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $17.18
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $17.82
Upside: +62.74%